載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$12.04
+US$1.32 · +12.31%
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
一般交易時段
US$12.04
+US$1.32 · +12.31%
盤中時間採用ET。市場資料可能有所延遲。
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
日內區間
目前US$12.04
52週區間
目前US$12.04
盤中時間採用ET。市場資料可能有所延遲。
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
日內區間
目前US$12.04
52週區間
目前US$12.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | −4468.43萬 USD | 47.23萬 USD | — | 25.1萬 USD | 16.78萬 USD |
| 銷貨成本 | 11.92萬 USD | 47.23萬 USD | — | 25.1萬 USD | 16.78萬 USD |
| 毛利 | −4480.36萬 USD | — | — | — | — |
| 研究與開發 | 8603.56萬 USD | 5491萬 USD | 3236.2萬 USD | 2549.1萬 USD | 1758.6萬 USD |
| 銷售、一般及管理費用 | 5599.9萬 USD | 8823.7萬 USD | 4647.4萬 USD | 2602.7萬 USD | 4625.2萬 USD |
| 營業費用 | 9687.38萬 USD | 1.43億 USD | 7883.6萬 USD | 5151.8萬 USD | 6383.8萬 USD |
| 利息收入 | 506.75萬 USD | 828.9萬 USD | 61.9萬 USD | 60.3萬 USD | 24.1萬 USD |
| 折舊和攤銷 | 12萬 USD | 47.23萬 USD | 42.4萬 USD | 25.1萬 USD | 16.8萬 USD |
| 營業利益 | −1.42億 USD | −1.43億 USD | −7883.6萬 USD | −5151.8萬 USD | −6383.8萬 USD |
| 淨利 | −1.47億 USD | −1.13億 USD | −7808萬 USD | −4749萬 USD | −6763.1萬 USD |
公司資料更新於 2026年10月9日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.00
上漲空間 82.72%評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
AdvisorShares Psychedelics ETFPSIL386.08萬8.48%4551.06萬 USD1.84%US$21.86+4.14%
Fidelity Nasdaq Composite Index ETFONEQ32.41萬—109.4億 USD0.21%US$107.8+0.62%
State Street SPDR S&P International Small Cap ETFGWX31.96萬0.03%9.18億 USD0.40%US$45.56+0.93%
Invesco NASDAQ Future Gen 200 ETFQQQS10.93萬0.49%2270.6萬 USD0.20%US$42.06+1.18%
T. Rowe Price Innovation Leaders ETFTNXT9395.940.05%1942.65萬 USD0.49%US$29.10+1.03%AdvisorShares Psychedelics ETFPSILFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXInvesco NASDAQ Future Gen 200 ETFQQQST. Rowe Price Innovation Leaders ETFTNXTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
